John E. Thompson - Waterloo, CA Bruce C. Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Adrienne Boone - Waterloo, CA Elizabeth Heikkila - Waterloo, CA Dominic Cliche - Kitchner, CA Shelley Culp-Stewart - Brandford, CA John Gerard Flanagan - Waterloo, CA Michelle Senchyna - Fort Worth TX, US
Assignee:
Senesco Technologies, Inc. - New Brunswick NJ
International Classification:
C07H 21/04
US Classification:
536 245
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
Inhibition Of Apoptosis-Specific Eif-5A ("Eif-5A1") With Antisense Oligonucleotides And Sirna As Anti-Inflammatory Therapeutics
John Thompson - Waterloo, CA Bruce Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Charles Dinarello - Boulder CO, US Leonid Reznikov - Aurora CO, US Adrienne Boone - Waterloo, CA Marianne Hopkins - New Hamburg, CA
International Classification:
A61K 48/00 C07H 21/04 C07H 21/02 C12N 15/85
US Classification:
514044000, 435455000, 536023100
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A.
Use Of Apoptosis-Specific Eif-5A Sirnas And Antisense Polynucleotides To Inhibit/Suppress An Inflammatory Response
John Thompson - Waterloo, CA Bruce Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Charles Dinarello - Boulder CO, US Leonid Reznikov - Aurora CO, US Adrienne Boone - Waterloo, CA Marianne Hopkins - Kitchener, CA
International Classification:
A61K 48/00 C07H 21/02 C12N 15/87
US Classification:
514044000, 435455000, 536023100
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
Use Of Antisense Oligonucleotides Or Sirna To Suppress Expression Of Eif-5A1
John Thompson - Waterloo, CA Bruce Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Adrienne Boone - Waterloo, CA Elizabeth Helkkila - Waterloo, CA Dominic Cliche - Marieville, CA Shelley Culp-Stewart - Brantford, CA John Flanagan - Waterloo, CA Michelle Senchyna - Fort Worth TX, US
Assignee:
Senesco Technologies, Inc. - New Brunswick NJ
International Classification:
A61K 48/00 C07H 21/02
US Classification:
514044000, 536023100
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
Apoptosis-Specific Eif-5A And Polynucleotides Encoding Same
John Thompson - Waterloo, CA Bruce Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Charles Dinarello - Boulder CO, US Leonid Reznikov - Aurora CO, US Adrienne Boone - Waterloo, CA Marianne Hopkins - Kitchener, CA
International Classification:
A61K 48/00 C12N 15/09
US Classification:
514044000, 435455000
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis.
Inhibition Of Apoptosis-Specific Eif-5A(Elf-5A1") With Antisense Oligonucleotides And Sirna As Anti-Inflammatory Therapeutics
John E. Thompson - Waterloo, CA Bruce C. Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Charles Dinarello - Boulder CO, US Leonid Reznikov - Aurora CO, US Adrienne Boone - Waterloo, CA Marianne Hopkins - New Hamburg, CA
Assignee:
Senesco Technologies Inc. - New Brunswick NJ
International Classification:
A61K 31/713 C12N 5/071 C07H 21/02
US Classification:
514 44 A, 536 245, 435377
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.
Use Of Antisense Oligonucleotides Or Sirna To Suppress Expression Of Eif-5A1
John E. Thompson - Waterloo, CA Bruce C. Galton - Madison NJ, US Catherine Taylor - Waterloo, CA Adrienne Boone - Waterloo, CA Elizabeth Margaret Heikkila - Waterloo, CA Dominic Cliche - Marieville, CA Shelley Culp-Stewart - Brantford, CA John Gerard Flannagan - Waterloo, CA Michelle Senchyna - Fort Worth TX, US
International Classification:
C12N 15/113
US Classification:
536 245
Abstract:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.